Maintenance therapy for advanced non-small-cell lung cancer: A pilot study on patients' perceptions

Journal of Thoracic Oncology

Volumn 7, Issue 8, 2012, Pages 1291-1295

  Peeters, Lies ^a   Sibille, Anne ^a   Anrys, Bea ^a   Oyen, Christel ^a   Dooms, Christophe ^a   Nackaerts, Kristiaan ^a   Wauters, Isabelle ^a   Vansteenkiste, Johan ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Chemotherapy; Maintenance treatment; Nonsmall cell lung cancer; Patients attitudes; Questionnaires; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; ERLOTINIB; PEMETREXED; PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; DIARRHEA; FATIGUE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT ATTITUDE; PERCEPTION; PILOT STUDY; PRIORITY JOURNAL; RASH;

EID: 84863853923     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31825879ea     Document Type: Article

References (14)

1. Felip E, Gridelli C, Baas P, Rosell R, Stahel R; Panel Members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol 2011;22:1507-1519.
2. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:64-70.
3. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
4. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-1234.
5. Pirker R, Pereira JR, Szczesna A, et al. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-1531.
6. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363: 1693-1703.
8. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second- line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2002;20:1335-1343.
9. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
10. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-529.
11. Goldstraw P, Crowley J, Chansky K, et al. International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
12. Sibille A, Wauters I, Vansteenkiste J. Maintenance therapy for advanced non-small-cell lung cancer: ready for clinical practice? Expert Rev Anticancer Ther 2012;12:529-539.
13. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998;317:771-775.
14. Dooms CA, Pat KE, Vansteenkiste JF. The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer. Expert Rev Anticancer Ther 2006;6:531-544.